CVKD
Cadrenal Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$1.22
−4.69%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +18.0%
- EBIT
- +19.1%
- EPS
- +44.9%
- Free cash flow
- +12.9%
- Operating cash flow
- +12.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +27.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- -24.2%
- EBIT
- -22.8%
- Net income
- -24.3%
- EPS
- +23.9%
- Free cash flow
- -71.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026